Clinical Trial

A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL)

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to find out whether the combination of epcoritamab and ibrutinib is a safe treatment approach that causes few or mild side effects in people with relapsed/refractory primary central nervous system lymphoma (PCNSL) or secondary central nervous system lymphoma (SCNSL).
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2025-07-17; most recent amendment 2026-07-13.
Status change: Not Yet Recruiting → Recruiting 2025-09-16
Trial Details
NCT Number NCT07082868
Lead Sponsor Memorial Sloan Kettering Cancer Center
Conditions Primary Central Nervous System Lymphoma (PCNSL), Primary Central Nervous System Lymphoma, Relapsed Primary Central Nervous System Lymphoma, Refractory Primary Central Nervous System Lymphoma, Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma (SCNSL)
Enrollment 26 participants
Start Date 2025-08-13
Primary Completion 2028-08 (estimated)
Study Completion 2028-08 (estimated)
Updated on ClinicalTrials.gov 2026-07-14